Home › Research › Biomarkers
T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation
Lorenzo Gualco, Noemi Montobbio, Mattia Losa, Mauro Costagli, Federico Massa, Beatrice Orso, Lucia Argenti, Enrico Peira et al.. European Radiology Experimental, 2026-09-21
Topic: Amyloid, tau and blood-test diagnosis
Thirty-three AD subjects, aged 69.3 ± 8.2 years (mean ± standard deviation), 18 females, and 22 HCs aged 70.5 ± 13.3 years, 15 females, were evaluated. Regional hippocampal qT1 was higher in AD (1,398 ± 53.0 ms versus 1,349 ± 53.4 ms; p = 0.002), without difference across cognitive subgroups stratified by MMSE. AD subjects exhibited increased qT1 in mesial temporal gray matter and temporo-parieto-occipital cortices (1,448 ± 55.7 ms versus 1,344 ± 51.6 ms; p < 0.001). Voxel-level modelling revealed a positive association between qT1 and amyloid-PET SUVr (p < 0.001; d = 0.223). qT1 mapping can be sensitive to changes related to brain amyloidosis, supporting its role as a promising, noninvasive imaging biomarker in AD. KEY POINTS: Question Can qT1 mapping detect AD-related microstructural changes in the cortico-limbic gray matter? Findings Participants with AD showed increased cortico-limbic qT1 values. A subtle yet consistent positive association was observed between cortical qT1 values and amyloid-PET SUVr. Relevance statement qT1 mapping captures microstructural tissue alterations related to amyloid pathology in Alzheimer's disease, supporting its role as a potential non-invasive imaging biomarker in this condition.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gualco, L., Montobbio, N., Losa, M., Costagli, M., Massa, F., Orso, B., et al. (2026). T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation. European Radiology Experimental. https://doi.org/10.1186/s41747-026-00792-1
Vancouver
Gualco L, Montobbio N, Losa M, Costagli M, Massa F, Orso B, et al. T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation. European Radiology Experimental. 2026. doi:10.1186/s41747-026-00792-1. PMID: 42766053.
BibTeX
@article{gualco2026-42766053,
author = {Gualco, Lorenzo and Montobbio, Noemi and Losa, Mattia and Costagli, Mauro and Massa, Federico and Orso, Beatrice and Argenti, Lucia and Peira, Enrico and others},
title = {{T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation}},
journal = {European Radiology Experimental},
year = {2026},
doi = {10.1186/s41747-026-00792-1},
pmid = {42766053},
url = {https://doi.org/10.1186/s41747-026-00792-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Thirty-three AD subjects, aged 69.3 ± 8.2 years (mean ± standard deviation), 18 females, and 22 HCs aged 70.5 ± 13.3 years, 15 females, were evaluated.
- Regional hippocampal qT1 was higher in AD (1,398 ± 53.0 ms versus 1,349 ± 53.4 ms; p = 0.002), without difference across cognitive subgroups stratified by MMSE.
- AD subjects exhibited increased qT1 in mesial temporal gray matter and temporo-parieto-occipital cortices (1,448 ± 55.7 ms versus 1,344 ± 51.6 ms; p < 0.001).
- Voxel-level modelling revealed a positive association between qT1 and amyloid-PET SUVr (p < 0.001; d = 0.223). qT1 mapping can be sensitive to changes related to brain amyloidosis, supporting its role as a promising, noninvasive imaging biomarker in AD.
- KEY POINTS: Question Can qT1 mapping detect AD-related microstructural changes in the cortico-limbic gray matter?
Why it matters
In 33 AD subjects and 22 healthy controls, a quantitative MRI measure called qT1 was higher in AD in several brain regions and was positively associated with amyloid PET. This small study supports qT1 mapping as a potential noninvasive imaging biomarker, not a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants16
- Evidence strengthLow
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 31 of the 64 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European Radiology Experimental) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 16 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42766053) |
| Free to read | 2 / 2 | Free to read |
| Points | 31 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 31 of the 64 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers
Also tagged “classification”
835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.